Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
58 studies found for:    Elvitegravir[TREATMENT] AND HIV [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
Elvitegravir[TREATMENT] AND HIV [CONDITION] (58 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed
Has Results
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Condition: HIV Infection
Interventions: Drug: Elvitegravir;   Drug: Raltegravir;   Drug: EVG placebo;   Drug: RAL placebo;   Drug: Background regimen
2 Completed Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
Condition: HIV Disease
Intervention: Drug: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
3 Active, not recruiting Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Condition: HIV Infection
Intervention: Drug: Treatment simplification
4 Active, not recruiting Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions: Drug: EVG;   Drug: Background regimen
5 Completed
Has Results
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: Stribild
6 Active, not recruiting Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: EVG/COBI/FTC/TDF
7 Active, not recruiting Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
Condition: HIV
Interventions: Drug: Stribild;   Drug: Genvoya
8 Recruiting Strategy for Maintenance of HIV Suppression With Elvitegravir + Darunavir/Ritonavir in Children
Condition: HIV Infection
Interventions: Drug: EVG +DRV/r;   Drug: SOC
9 Unknown  Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Condition: HIV
Interventions: Drug: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra);   Drug: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
10 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: NNRTI;   Drug: FTC/TDF;   Drug: Stribild
11 Active, not recruiting Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: E/C/F/TAF
12 Completed SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers
Condition: HIV
Intervention: Drug: Dolutegravir, Elvitegravir and Cobicistat
13 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: PI;   Drug: RTV;   Drug: FTC/TDF;   Drug: Stribild
14 Active, not recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
15 Not yet recruiting Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting
Condition: HIV
Intervention: Drug: prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir
16 Active, not recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV
17 Completed Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
Conditions: HIV;   HIV-1;   Human Immunodeficiency Virus
Intervention: Drug: GS-9137 - A Novel HIV-1 Integrase Inhibitor
18 Not yet recruiting Early ART to Limit Infection and Establishment of Reservoir
Condition: HIV-1 Infection
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
19 Active, not recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
20 Completed
Has Results
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Condition: HIV Infections
Interventions: Drug: EVG;   Drug: RTV;   Drug: ARV regimen

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.